Physician profile
Mark E Collins
NPI 1255368494
$4,396.71
in general payments reported to CMS, 2019-2025
28 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $553 · 2021: $715 · 2022: $710 · 2023: $607 · 2024: $665 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $578.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $528.97 | 2019-2022 | |
| Pfizer INC. | $443.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.44 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $237.84 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $218.02 | 2019-2024 | Farxiga, Lokelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.71 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $210.67 | 2023-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $182.60 | 2019-2023 | Belsomra, Verquvo, Steglujan |
| Lilly USA, LLC | $179.12 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $176.76 | 2019-2025 | Evenity, Prolia, Prolia |
| Avanir Pharmaceuticals, INC. | $148.85 | 2019-2022 | |
| Mylan Specialty L.P. | $143.30 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $141.64 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $109.37 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $100.53 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $61.58 | 2019-2021 | |
| Lundbeck LLC | $46.53 | 2023-2024 | Rexulti |
| Ge Healthcare | $43.69 | 2019-2025 | |
| Astellas Pharma US INC | $38.93 | 2019 | |
| Glaxosmithkline, LLC. | $37.84 | 2020-2025 | Shingrix, Arexvy |
| Eisai INC. | $33.86 | 2020-2021 | |
| Rgh Enterprises LLC | $19.31 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.83 | 2023 | Rebyota |
| Paratek Pharmaceuticals, INC. | $17.03 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.84 | 2019 | |
| Welch Allyn | $14.25 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.